Abstracts tagged "Cardiovascular disease"

Abstract Number: 2075 • 2018 ACR/ARHP Annual Meeting
Vascular Endothelial and Inflammatory Differences in Psoriasis and Psoriatic Arthritis Patients
Michael Gashick¹, Todd Wechter², Tessa Barrett¹, Sarah Azarchi², Stuart Katz³, Andrea L. Neimann⁴, James Krueger⁵, Sanja Jelic⁶, Edward Fisher¹, Jose U. Scher⁷ and Jeffrey S. Berger⁸, ¹Medicine/Cardiology, New York University School of Medicine, New York City, NY, ²Dermatology, New York University School of Medicine, New York City, NY, ³Medicine/Cardiology, New York University School of Medicine, New York, NY, ⁴Department of Dermatology, New York University School of Medicine, New York, NY, ⁵The Rockefeller University, New York, NY, ⁶Medicine/Pulmonary, Columbia University Medical Center, New York City, NY, ⁷New York University School of Medicine, New York, NY, ⁸Medicine, Division of Cardiology, New York University School of Medicine, New York, NY
Background/Purpose: Psoriatic arthritis (PsA) and Psoriasis (PsO) are chronic inflammatory diseases associated with vascular inflammation and increased CVD risk. Few studies have examined vascular inflammatory…
Abstract Number: 2847 • 2018 ACR/ARHP Annual Meeting
Associations between Serum Uric Acid Level and Coronary Artery Disease
Patricia Kachur^1,2, Satish Tadepalli³, Sergey Kachur⁴ and Pramil Cheriyath³, ¹Rheumatolgy, Ochsner Foundation Hospital, New Orleans, LA, ²Internal Medicine, Ocala Regional Medical Center, Ocala, FL, ³Hackensack Meridian Health, Ocean Medical Center, Brick, NJ, ⁴Ocala Regional Medical Center, Ocala, FL
Title: Association between Serum Uric Acid Level and Coronary Artery DiseaseBackground/Purpose: Previous studies have shown an unclear relationship between serum uric acid (SUA) and coronary…
Abstract Number: 509 • 2018 ACR/ARHP Annual Meeting
Cardiovascular Disease Risk Factors May Negatively Impact Rheumatoid Arthritis Disease Outcomes: Findings from the Ontario Best Practices Research Initiative
Kathy Cui¹, Mohammad Movahedi², Claire Bombardier³ and Bindee Kuriya^4,5,6, ¹Western University, London Health Sciences Centre, London, ON, Canada, ²JSS Medical Research, St-Laurent, QC, Canada, ³Toronto General Hospital Research Institute, University Health Network, Toronto, ON, Canada, ⁴Rheumatology, Mount Sinai Hospital, University of Toronto, Toronto, ON, Canada, ⁵Sinai Health System, University of Toronto, Toronto, ON, Canada, ⁶Rheumatology, University of Toronto, Toronto, ON, Canada
Background/Purpose: Rheumatoid arthritis increases the risk of cardiovascular disease (CVD). Less is known about the direct influence of CVD on RA outcomes, but higher comorbidity…
Abstract Number: 863 • 2018 ACR/ARHP Annual Meeting
Combining Cardiac Magnetic Resonance and Right Heart Catheterization to Evaluate Right Ventricular Function for the Prognosis Prediction in Patients with Connective Tissue Diseases and Pulmonary Hypertension
Nobuya Abe¹, Masaru Kato², Hiroyuki Nakamura², Atsushi Noguchi², Yuichiro Fujieda², Kenji Oku², Toshiyuki Bohgaki², Olga Amengual², Shinsuke Yasuda² and Tatsuya Atsumi², ¹Department of Rheumatology, Endocrinology and Nephrology, Graduate School of Medicine, Hokkaido University, Sapporo, Japan, ²Department of Rheumatology, Endocrinology and Nephrology, Faculty of Medicine and Graduate School of Medicine, Hokkaido University, Sapporo, Japan
Background/Purpose: Pulmonary arterial hypertension associated with connective tissue diseases (CTD-PAH), particularly PAH associated with systemic sclerosis (SSc-PAH), has a poor prognosis compared with other PAH.…
Abstract Number: 1593 • 2018 ACR/ARHP Annual Meeting
Extra-Articular Manifestations, Neoplasms and Cardiovascular Events in a Series of Spondyloarthritis from a Single Center
Itziar Calvo Zorrilla¹, Edurne Guerrero Basterretxea¹, Oihane Ibarguengoitia¹, David Montero¹, Maria Luz Garcia Vivar¹, Esther Ruíz Lucea², Ignacio Torre Salaberri², Olaia Begoña Fernandez Berrizbeitia², Juan Maria Blanco Madrigal², Ana Rosa Inchaurbe Pellejero¹, Clara Eugenia Perez Velasquez², Natalia Rivera-García³, Maria Jesus Allande Lopez Linares³, Iñigo Gorostiza-Hormaetxe⁴ and Eva Galíndez Agirregoikoa², ¹Rheumatology, Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ²Rheumatology Department; Basurto University Hospital, Bilbao, Spain, ³Rheumatology, University Hospital of Basurto, Bilbao, Spain, ⁴Research Department, Basurto University Hospital, Bilbao, Spain
Background/Purpose: Spondyloarthritis(SpA) is characterized by axial, peripheral and extra-articular manifestation(EAMs). Its frequency depends on the series, being the psoriasis(Ps), uveitis and inflammatory bowel disease(IBD) the…
Abstract Number: 2164 • 2018 ACR/ARHP Annual Meeting
IMPACT of a Systematic Screening of Multimorbidities in Patients with Chronic Inflammatory Rheumatic Diseases
Mégane Beurai-Weber Jr.¹, Audrey Jaussent², Guilhem du Cailar³, Marie-Christine Picot², François Roubille Sr.⁴, Jean-David Cohen⁵, Jacques Morel⁶, Jean Bousquet⁷, Pierre Fesler⁸, Bernard Combe⁹ and Claire Daien¹⁰, ¹Rheumatology Department, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ²Department of medical information, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ³Internal Medicine and Hypertension, Hopital Lapeyronie, Montpellier, France, ⁴Department of cardiology, Arnaud de Villeneuve Hospital and Montpellier University, MONTPELLIER, France, ⁵IMMUNO-RHEUMATOLOGY, CHU LAPEYRONIE, MONTPELLIER, France, ⁶Department of Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France, ⁷MACVIA-France, Lapeyronie Hospital and Montpellier University, MONTPELLIER, France, ⁸Internal medicine and hypertension, Lapeyronie Hospital and Montpellier University, Montpellier, France, ⁹University Hospital Lapeyronie, Department of Rheumatology, Montpellier, France, ¹⁰Rheumatology, University Hospital Lapeyronie, Montpellier, Montpellier, France
Background/Purpose: EULAR proposes to screen multimorbidities in chronic inflammatory rheumatic diseases. The aim of the study was to assess i) multimorbidities in patients with chronic…
Abstract Number: 2859 • 2018 ACR/ARHP Annual Meeting
Do Preventive Cardiology Consults Versus Usual Care Improve Cardiovascular Risk Factor Assessment and Management in Patients with Rheumatoid Arthritis?
Ellen Romich¹, Haitham Ahmed², Amy Nowacki³ and M. Elaine Husni⁴, ¹Cleveland Clinic Lerner College of Medicine of Case Western Reserve University, Cleveland, OH, ²Cardiovascular Medicine, Cleveland Clinic, Cleveland, OH, ³Quantitative Health Sciences, Cleveland Clinic, Cleveland, OH, ⁴Rheumatology, Cleveland Clinic, Cleveland, OH
Background/Purpose: Rheumatoid arthritis (RA) patients have around 50% increased risk of cardiovascular disease (CVD). Both traditional and RA-specific cardiovascular (CV) risk factors contribute to the…
Abstract Number: 511 • 2018 ACR/ARHP Annual Meeting
Identifying Vulnerable Plaque in Rheumatoid Arthritis Using Novel Microbubble Contrast-Enhanced Carotid Ultrasonography and Serum Biomarkers of Inflammation and Atherosclerosis
Linda F. Wang¹, Yaming Li², Douglas Landsittel³, Suresh R. Mulukutla⁴, Steven Reis⁵, Marc Levesque⁶, Donald M. Jones⁷, Rachel Gartland⁶, Jennifer Avolio⁸, Ali Hakim Shoushtari⁸, Flordeliza Villanueva⁵, Larry W. Moreland⁹ and Kimberly P. Liang⁶, ¹School of Medicine, University of Pittsburgh, Pittsburgh, PA, ²Biostatistics, University of Pittsburgh, Pittsburgh, PA, ³Biomedical Informatics, University of Pittsburgh, Pittsburgh, PA, ⁴Division of Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁵Cardiology, University of Pittsburgh, Pittsburgh, PA, ⁶Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁷Division of Rheumatology and Clinical Immunology, University of Pittsburgh, Pittsburgh, PA, ⁸Clinical and Translational Science Institute, University of Pittsburgh, Pittsburgh, PA, ⁹Rheumatology & Clinical Immunology, University of Pittsburgh, Pittsburgh, PA
Background/Purpose: Rheumatoid arthritis (RA) patients have an elevated risk of cardiovascular (CV) disease unexplained by traditional CV risk factors. Markers of systemic inflammation, including those…
Abstract Number: 872 • 2018 ACR/ARHP Annual Meeting
Is the Serum Uric Acid Therapeutic Target Protective of Chronic Kidney Disease, Cardiovascular Disease, and Mortality for Patients with Gout? a Longitudinal Study
Douglas C.A. Taylor¹, Dena Jaffe², Moshe Hoshen³, Galit Shefer³, Asaf Bachrach³, Becca Feldman³, An-Chen Fu¹ and Hyon K. Choi⁴, ¹Ironwood Pharmaceuticals, Inc., Cambridge, MA, ²Kantar Health, Tel Aviv, Israel, ³Clalit Research Institute, Tel Aviv, Israel, ⁴Division of Rheumatology, Allergy, and Immunology, Massachusetts General Hospital, Boston, MA
Background/Purpose: Many studies have found that serum uric acid (sUA) levels are associated with the incidence of chronic kidney disease (CKD), cardiovascular disease (CVD), and…
Abstract Number: 1596 • 2018 ACR/ARHP Annual Meeting
Atherosclerotic Cardiovascular Disease in Psoriatic Arthritis: Evaluation of Risk Factor Management and Use of Aspirin and Statin for Prevention in a Primary Care Setting
Linh Truong¹, Nicole Ridolfi¹ and Maida Wong^2,3, ¹Internal Medicine, University of California, Irvine, Orange, CA, ²Department of Medicine, University of California, Irvine, orange, CA, ³Division of Rheumatology, Tibor Rubin Veterans Affairs Medical Center Long Beach, Long Beach, CA
Background/Purpose: There is accumulating evidence that shows an increased prevalence of atherosclerotic cardiovascular disease (ASCVD) risk factors among the psoriatic arthritis (PsA) population. The aim…
Abstract Number: 2171 • 2018 ACR/ARHP Annual Meeting
A 5-Year National Trend in Acute Myocardial Infarctionamong Hospitalized Patients with Psoriatic Arthritis: Data from National Inpatient Sample
Shraddha Jatwani¹, Karan Chugh², Karan Jatwani³, Vivek Modi⁴ and Jasleen Kaur⁵, ¹Department of Internal Medicine, Division of Rheumatology, Henry Ford Allegiance Health, Jackson, MI, ²Division of Pulmonary, Critical Care & Sleep, Wayne State University/Detroit Medical Center, Detroit, MI, ³Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital, New York, NY, ⁴Department of Internal Medicine, Mount Sinai West - St Luke’s Hospital,, New York, NY, ⁵Department of Internal Medicine, Wayne State University/Detroit Medical Center, Detroit, MI
Background/Purpose: Psoriatic arthritis (PsA) is associated with an increased risk of cardiovascular morbidity and mortality. The increase in cardiovascular risk evaluated in a meta-analysis on…
Abstract Number: 2934 • 2018 ACR/ARHP Annual Meeting
Myocardial Microscopic Fibrosis Assessed By T1 Mapping Sequences on Cardiac Magnetic Resonance Imaging Predicts Cardiac Events in Systemic Sclerosis: Data from a Prospective Cohort Study on 40 Patients
Benjamin Terrier¹, Agnès Dechartres², Hervé Gouya³, Alexis Régent⁴, Bertrand Dunogué⁵, Pascal Cohen⁶, Alice Berezne⁷, Claire Le Jeunne⁸, Paul Legmann³, Olivier Vignaux³ and Luc Mouthon⁹, ¹National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France, ²Epidemiology, Hotel Dieu, Paris, France, ³Radiology, Cochin hospital, Paris, France, ⁴Department of Internal Medicine, Hôpital Cochin, Assistance Publique-Hôpitaux de Paris (APHP), Université Paris Descartes, Paris, France, ⁵Internal Medicine, Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁶Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, Hôpital Cochin, Université Paris Descartes, Sorbonne Paris Cité, Paris, France, ⁷Internal Medicine, CH Annecy, Annecy, France, ⁸Department of Internal Medicine, National Referral Center for Rare Systemic Autoimmune Diseases, Hôpital Cochin, AP–HP, Université Paris Descartes, Paris, France, ⁹Department of Internal Medicine, INSERM Unité 1016, Centre de Référence pour les Maladies Auto-immunes Rares, National Referral Center for Rare Systemic Autoimmune Diseases, Paris Cochin, France, Paris, France
Background/Purpose: Studies have shown that myocardial involvement may occur in systemic sclerosis (SSc) and lead to cardiac failure. We showed previously that cardiac magnetic resonance…
Abstract Number: 200 • 2018 ACR/ARHP Annual Meeting
Validation of the Ers-RA Risk Score in a Dutch Population
Milad Baniaamam¹ and Michael Nurmohamed², ¹Department of rheumatology, Amsterdam Rheumatology immunology Center | Reade and VU University Medical Center Amsterdam, Netherlands, Amsterdam, Netherlands, ²Rheumatology, VU University Medical Center, Amsterdam, Netherlands
Background/Purpose: The most frequent cause of death in patients with chronic rheumatoid arthritis (RA) is of cardiovascular (CV) origin. CV risk prediction scores in the…
Abstract Number: 512 • 2018 ACR/ARHP Annual Meeting
Incidence of First Cardiovascular Event in Spanish Patients with Chronic Inflammatory Rheumatic Diseases: Prospective Data from an Observational Multicentric Study
Maria Auxiliadora Martin¹, Santos Castañeda², Carlos González-Juanatey³, Fernando Sánchez-Alonso⁴, María Carmen García-Gómez⁵, R López-González⁶, Jesus Babio⁷, Antonio Juan-Mas⁸, María P Moreno-Gil⁹, Olga Sanchez-González¹⁰, Montserrat Romera¹¹, Jose A Pinto-Tasende¹², Jose A Piqueras¹³, Dolores Fábregas¹⁴, Javier Llorca¹⁵ and Miguel Angel González-Gay¹⁶, ¹Research Unit of Spanish Society of Rheumatology,, Madrid, Spain, ²Hospital Universitario La Princesa, IIS-Princesa, Madrid, Spain, ³Cardiology Division, Hospital Xeral-Calde, Lugo, Spain, ⁴Unidad de Investigación, Spanish Society of Rheumatology, Madrid, Spain, ⁵Rheumatology Division, Consorci Sanitari de Terrassa, Terrassa (Barcelona), Spain, ⁶Rheumatology, Complejo Hospitalario de Zamora. Spain, Zamora, Spain, ⁷Rhaumatology, H General de Cabueñes, Gijon, Spain, ⁸Division of Rheumatology, Hospital Son Llatzer, Palma de Mallorca, Spain, Spain, ⁹Division of Rheumatology, Hospital San Pedro de Alcántara, Cáceres, Spain, ¹⁰Division of Rheumatology, Hospital del Sureste, Madrid, Spain, ¹¹Division of Rheumatology, Hospital de Bellvitge, Barcelona, Spain, ¹²Complejo Hospitalario Universitario de A Coruña, A Coruña, Spain, ¹³Division of Rheumatology, Hospital Universitario de Guadalajara, Guadalajara, Spain, ¹⁴Division of Rheumatology, Hospital de Barbastro, Huesca, Spain, ¹⁵Department of Epidemiology and Computational Biology, School of Medicine, University of Cantabria, and CIBER Epidemiología y Salud Pública (CIBERESP), IDIVAL, Santander, Spain, Santander, Spain, ¹⁶School of Medicine, University of Cantabria, Santander, Spain, Santander, Spain
Background/Purpose: To determine the incidence and risk factors implicated in the development of first cardiovascular event (CVE) in patients with chronic inflammatory rheumatic diseases (CIRD)…
Abstract Number: 873 • 2018 ACR/ARHP Annual Meeting
General Safety of Febuxostat and Allopurinol in a Cardiovascular Outcomes Study in Patients with Gout
Kenneth Saag¹, Michael A. Becker², William B. White³, Andrew Whelton⁴, Jeffrey Borer⁵, Philip Gorelick⁶, Barbara Hunt⁷, Majin Castillo⁷ and Lhanoo Gunawardhana⁷, ¹University of Alabama at Birmingham, Birmingham, AL, ²University of Chicago Pritzker School of Medicine, Chicago, IL, ³Cardiology, University of Connecticut School of Medicine, Farmington, CT, ⁴Johns Hopkins University School of Medicine, Hunt Valley, MD, ⁵State University of New York Downstate Medical Center, Brooklyn, NY, ⁶Michigan State University College of Human Medicine, Grand Rapids, MI, ⁷Takeda Pharmaceuticals International, Deerfield, IL
Background/Purpose: The cardiovascular (CV) safety study CARES has the longest study duration of any randomized controlled trial in patients (pts) with gout and CV disease.…

« Previous Page
1
…
4
5
6
7
8
…
38
Next Page »

All abstracts accepted to ACR Convergence are under media embargo once the ACR has notified presenters of their abstract’s acceptance. They may be presented at other meetings or published as manuscripts after this time but should not be discussed in non-scholarly venues or outlets. The following embargo policies are strictly enforced by the ACR.

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of our scientific journal, Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. In an exception to the media embargo, academic institutions, private organizations, and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part of editorial news coverage) is under media embargo until 10:00 AM ET on November 14, 2024. Journalists with access to embargoed information cannot release articles or editorial news coverage before this time. Editorial news coverage is considered original articles/videos developed by employed journalists to report facts, commentary, and subject matter expert quotes in a narrative form using a variety of sources (e.g., research, announcements, press releases, events, etc.).

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying colleagues, institutions, communications firms, and all other stakeholders related to the development or promotion of the abstract about this policy. If you have questions about the ACR abstract embargo policy, please contact ACR abstracts staff at [email protected].

ACR Abstract Embargo Policy

Accepted abstracts are made available to the public online in advance of the meeting and are published in a special online supplement of Arthritis & Rheumatology. Information contained in those abstracts may not be released until the abstracts appear online. Academic institutions, private organizations and companies with products whose value may be influenced by information contained in an abstract may issue a press release to coincide with the availability of an ACR abstract on the ACR website. However, the ACR continues to require that information that goes beyond that contained in the abstract (e.g., discussion of the abstract done as part a scientific presentation or presentation of additional new information that will be available at the time of the meeting) is under embargo until Saturday, November 11, 2023.

Violation of this policy may result in the abstract being withdrawn from the meeting and other measures deemed appropriate. Authors are responsible for notifying financial and other sponsors about this policy. If you have questions about the abstract embargo policy, please contact the public relations department at [email protected].

Copyright Policy

View ACR Policies.